The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine

Abstract Pancreatic cancer is one of the most lethal and chemo-resistant cancers worldwide. Growing evidence supports the theory that the gut microbiota plays an essential role in modulating the host response to anti-cancer therapy. The present study aimed to explore the effect of probiotics as an a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shan-Ming Chen, Wee-Wei Chieng, Szu-Wei Huang, Li-Jin Hsu, Ming-Shiou Jan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
R
Q
Acceso en línea:https://doaj.org/article/15cf03039bce4227a77ea1f341924212
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:15cf03039bce4227a77ea1f341924212
record_format dspace
spelling oai:doaj.org-article:15cf03039bce4227a77ea1f3419242122021-12-02T15:09:23ZThe synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine10.1038/s41598-020-77322-52045-2322https://doaj.org/article/15cf03039bce4227a77ea1f3419242122020-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-77322-5https://doaj.org/toc/2045-2322Abstract Pancreatic cancer is one of the most lethal and chemo-resistant cancers worldwide. Growing evidence supports the theory that the gut microbiota plays an essential role in modulating the host response to anti-cancer therapy. The present study aimed to explore the effect of probiotics as an adjuvant during chemotherapy for pancreatic cancer. An LSL-Kras G12D/− -Pdx-1-Cre mouse model of pancreatic ductal adenocarcinoma (PDAC) was created to study the effects of using four-week multi-strain probiotics (Lactobacillus paracasei GMNL-133 and Lactobacillus reuteri GMNL-89) as an adjuvant therapy for controlling cancer progression. At 12 weeks of age, pancreatitis was induced in the mice by two intraperitoneal injection with caerulein (25 μg/kg 2 days apart). Over the next 4 weeks the mice were treated with intraperitoneal injections of gemcitabine in combination with the oral administration of probiotics. The pancreas was then harvested for analysis. Following caerulein treatment, the pancreases of the LSL-Kras G12D/− -Pdx-1-Cre transgenic mice exhibited more extensive pancreatic intraepithelial neoplasia (PanIN) formation. Combined treatment with gemcitabine and probiotics revealed a lower grade of PanIN formation and a decrease in the expression of vimentin and Ki-67. Mice that received gemcitabine in combination with probiotics had lower aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Notably, the use of high-dose probiotics alone without gemcitabine also had an inhibitory effect on PanIN changes and serum liver enzyme elevation. These findings suggest that probiotics are able to make standard chemotherapy more effective and could help improve the patient’s tolerance of chemotherapy.Shan-Ming ChenWee-Wei ChiengSzu-Wei HuangLi-Jin HsuMing-Shiou JanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Shan-Ming Chen
Wee-Wei Chieng
Szu-Wei Huang
Li-Jin Hsu
Ming-Shiou Jan
The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine
description Abstract Pancreatic cancer is one of the most lethal and chemo-resistant cancers worldwide. Growing evidence supports the theory that the gut microbiota plays an essential role in modulating the host response to anti-cancer therapy. The present study aimed to explore the effect of probiotics as an adjuvant during chemotherapy for pancreatic cancer. An LSL-Kras G12D/− -Pdx-1-Cre mouse model of pancreatic ductal adenocarcinoma (PDAC) was created to study the effects of using four-week multi-strain probiotics (Lactobacillus paracasei GMNL-133 and Lactobacillus reuteri GMNL-89) as an adjuvant therapy for controlling cancer progression. At 12 weeks of age, pancreatitis was induced in the mice by two intraperitoneal injection with caerulein (25 μg/kg 2 days apart). Over the next 4 weeks the mice were treated with intraperitoneal injections of gemcitabine in combination with the oral administration of probiotics. The pancreas was then harvested for analysis. Following caerulein treatment, the pancreases of the LSL-Kras G12D/− -Pdx-1-Cre transgenic mice exhibited more extensive pancreatic intraepithelial neoplasia (PanIN) formation. Combined treatment with gemcitabine and probiotics revealed a lower grade of PanIN formation and a decrease in the expression of vimentin and Ki-67. Mice that received gemcitabine in combination with probiotics had lower aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Notably, the use of high-dose probiotics alone without gemcitabine also had an inhibitory effect on PanIN changes and serum liver enzyme elevation. These findings suggest that probiotics are able to make standard chemotherapy more effective and could help improve the patient’s tolerance of chemotherapy.
format article
author Shan-Ming Chen
Wee-Wei Chieng
Szu-Wei Huang
Li-Jin Hsu
Ming-Shiou Jan
author_facet Shan-Ming Chen
Wee-Wei Chieng
Szu-Wei Huang
Li-Jin Hsu
Ming-Shiou Jan
author_sort Shan-Ming Chen
title The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine
title_short The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine
title_full The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine
title_fullStr The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine
title_full_unstemmed The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine
title_sort synergistic tumor growth-inhibitory effect of probiotic lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine
publisher Nature Portfolio
publishDate 2020
url https://doaj.org/article/15cf03039bce4227a77ea1f341924212
work_keys_str_mv AT shanmingchen thesynergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT weeweichieng thesynergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT szuweihuang thesynergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT lijinhsu thesynergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT mingshioujan thesynergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT shanmingchen synergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT weeweichieng synergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT szuweihuang synergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT lijinhsu synergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
AT mingshioujan synergistictumorgrowthinhibitoryeffectofprobioticlactobacillusontransgenicmousemodelofpancreaticcancertreatedwithgemcitabine
_version_ 1718387798172499968